Savara, Inc. (SVRA) News
Filter SVRA News Items
SVRA News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
SVRA News Highlights
- SVRA's 30 day story count now stands at 3.
- Over the past 6 days, the trend for SVRA's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- The most mentioned tickers in articles about SVRA are RARE, GM and LUNG.
Latest SVRA News From Around the Web
Below are the latest news stories about SAVARA INC that investors may wish to consider to help them evaluate SVRA as an investment opportunity.
Savara Introduces aPAP ClearPath™, a GM-CSF Autoantibody Blood Test to Detect Autoimmune Pulmonary Alveolar Proteinosis (aPAP)LANGHORNE, Pa., December 21, 2023--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, recently launched aPAP ClearPath™, a new serum-based blood test that can be used by physicians in the U.S. to obtain a definitive diagnosis of aPAP, a rare autoimmune lung disease mediated by autoantibodies targeting GM-CSF. Autoimmune PAP accounts for approximately 90% of all patients with PAP and has an estimated diagnosed prevalence of s |
Savara Added to the NASDAQ Biotechnology IndexLANGHORNE, Pa., December 20, 2023--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that the company was added to the NASDAQ Biotech Index (Nasdaq: NBI), effective prior to market open on Monday, December 18, 2023. |
Savara Announces New Employment Inducement GrantAUSTIN, Texas, December 15, 2023--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to a new employee. |
Savara Inc. (NASDAQ:SVRA) most popular amongst private equity firms who own 41% of the shares, institutions hold 31%Key Insights Savara's significant private equity firms ownership suggests that the key decisions are influenced by... |
Savara to Present at the Piper Sandler 35th Annual Healthcare ConferenceLANGHORNE, Pa., November 21, 2023--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will participate in a fireside chat at the Piper Sandler 35th Annual Healthcare Conference on November 28, 2023 at 1:00pm PT/4:00pm ET. A live webcast of the fireside chat will be available on Savara’s website at www.savarapharma.com/investors/events-presentations/ and will be archived for 90 days. |
Savara Reports Third Quarter Financial Results and Provides Business UpdateLANGHORNE, Pa., November 09, 2023--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the third quarter ending September 30, 2023 and provided a business update. |
Savara to Present at the Jefferies London Healthcare ConferenceLANGHORNE, Pa., November 08, 2023--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will participate in a fireside chat at the Jefferies London Healthcare Conference on November 15, 2023 at 12:00pm GMT/7:00am EST. A live webcast of the fireside chat will be available on Savara’s website at www.savarapharma.com/investors/events-presentations/ and will be archived for 90 days. |
Bullish Savara Insiders Loaded Up On US$611.8k Of StockIt is usually uneventful when a single insider buys stock. However, When quite a few insiders buy shares, as it... |
3 Penny Stocks to Provide 1,000% Returns Over the Next DecadePenny stocks offer opportunities with potential for substantial returns, fueling interest in the best picks. |
15 Penny Stocks with Biggest UpsideIn this article, we will take a look at the 15 penny stocks with biggest upside. To see more such companies, go directly to 5 Penny Stocks with Biggest Upside. Everyone wants to find stocks with upside. But the stock market turmoil that started back in 2022 amid rising inflation and interest rate hikes has […] |